Ginger Stewart
Family · Southaven, MSNPI 1275936163
Payments from drug & device makers
Across 445 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- AstraZeneca$644
- Bayer$475
- Amgen$279
- plus $2K from 32 others
What the payments were for
- Food & beverage$7,841100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $1,759 |
| Lilly USA, LLC | 83 | $1,278 |
| Novo Nordisk | 51 | $1,139 |
| AstraZeneca | 32 | $644 |
| Bayer | 23 | $475 |
| Amgen | 16 | $279 |
| Pfizer | 19 | $248 |
| GSK | 19 | $222 |
| Abbott | 10 | $208 |
| Boehringer Ingelheim | 11 | $191 |
| Boston Scientific | 7 | $134 |
| Johnson & Johnson | 7 | $115 |
| Phathom Pharmaceuticals, Inc. | 8 | $100 |
| Kowa Pharmaceuticals America, Inc. | 3 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $88 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $69 |
| Dexcom, Inc. | 3 | $66 |
| Shield Therapeutics Inc | 3 | $59 |
| Triad Life Sciences Inc. | 1 | $58 |
| Novartis | 2 | $55 |
| Arbor Pharmaceuticals, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 3 | $49 |
| Merck | 3 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| Exact Sciences | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Abiomed | 1 | $21 |
| Edwards Lifesciences | 1 | $19 |
| Lundbeck LLC | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Nestle Healthcare Nutrition Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$249
How this compares
$7,841 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 77 | $101,950 |
| MounjaroTirzepatide | 21 | $32,220 |
| TrulicityDulaglutide | 25 | $31,467 |
| OzempicSemaglutide | 23 | $23,190 |
| LinzessLinaclotide | 11 | $18,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,763 |
| EliquisApixaban | 15 | $14,363 |
| FarxigaDapagliflozin Propanediol | 13 | $11,482 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 44 | $1,485 |
| Ezetimibe | 28 | $1,274 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,234 |
| Gabapentin | 78 | $1,196 |
| Levetiracetam | 13 | $1,187 |
| Paroxetine Hcl | 25 | $1,001 |
| Duloxetine Hcl | 37 | $956 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $191 | $101,95077 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,278 | $63,68646 claims |
| Novo NordiskOzempic | $1,139 | $23,19023 claims |
| AbbVieLinzess, Synthroid | $1,759 | $18,71326 claims |
| GSKTrelegy Ellipta | $222 | $16,76317 claims |
| PfizerEliquis | $248 | $14,36315 claims |
| AstraZenecaFarxiga | $644 | $11,48213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Southaven
- Lindsey GarnerSouthaven$16K
- Angela UgwuanyiSouthaven$13K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.